As a greater number of drugs are distributed through specialty channels, it is difficult to gain deep insights into the patient journey. Single data sources provide limited visibility into the complex journeys for patients on specialty therapies.
Building External Control Arms through Real-World Data – A Phase II Oncology Case Study
